AU6854200A - Pharmaceutical composition comprising nabumetone - Google Patents

Pharmaceutical composition comprising nabumetone

Info

Publication number
AU6854200A
AU6854200A AU68542/00A AU6854200A AU6854200A AU 6854200 A AU6854200 A AU 6854200A AU 68542/00 A AU68542/00 A AU 68542/00A AU 6854200 A AU6854200 A AU 6854200A AU 6854200 A AU6854200 A AU 6854200A
Authority
AU
Australia
Prior art keywords
nabumetone
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68542/00A
Inventor
Paul John Cummings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU6854200A publication Critical patent/AU6854200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU68542/00A 1999-08-25 2000-08-25 Pharmaceutical composition comprising nabumetone Abandoned AU6854200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9920148 1999-08-25
GBGB9920148.5A GB9920148D0 (en) 1999-08-25 1999-08-25 Novel composition
PCT/GB2000/003312 WO2001013889A1 (en) 1999-08-25 2000-08-25 Pharmaceutical composition comprising nabumetone

Publications (1)

Publication Number Publication Date
AU6854200A true AU6854200A (en) 2001-03-19

Family

ID=10859799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68542/00A Abandoned AU6854200A (en) 1999-08-25 2000-08-25 Pharmaceutical composition comprising nabumetone

Country Status (5)

Country Link
EP (1) EP1207855A1 (en)
JP (1) JP2003507409A (en)
AU (1) AU6854200A (en)
GB (1) GB9920148D0 (en)
WO (1) WO2001013889A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1294358E (en) * 2000-06-28 2004-12-31 Smithkline Beecham Plc MOORING PROCESS BY HUMIDITY
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0516549D0 (en) 2005-08-12 2005-09-21 Sulaiman Brian Milling system
KR100715355B1 (en) * 2005-09-30 2007-05-07 주식회사유한양행 Spray-dried granules containing pranlukast and processes for the preparation thereof
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201857D0 (en) * 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
GB9828204D0 (en) * 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process

Also Published As

Publication number Publication date
GB9920148D0 (en) 1999-10-27
EP1207855A1 (en) 2002-05-29
WO2001013889A1 (en) 2001-03-01
JP2003507409A (en) 2003-02-25

Similar Documents

Publication Publication Date Title
PL351387A1 (en) Pharmaceutical composition
AU3192700A (en) Medicinal compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
AU3556400A (en) Pharmaceutical compositions
AU2005300A (en) Medicinal compositions
AU1887401A (en) Medicinal composition
ZA200000857B (en) Pharmaceutical composition.
AU6715600A (en) Pharmaceutical formulations
GB9904163D0 (en) Pharmaceutical compositions
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU6460400A (en) Pharmaceutical compositions
AU1730201A (en) Proteoglycans and pharmaceutical compositions comprising them
GB9911017D0 (en) Pharmaceutical compositions
AU4977300A (en) Pharmaceutical formulations
AU6460200A (en) Pharmaceutical compositions
AU1385801A (en) Pharmaceutical formulations
AU7012200A (en) Pharmaceutical compositions comprising 4-quinolones
AUPP332898A0 (en) Pharmaceutical composition
AU4085201A (en) Pharmaceutical composition
AU6854200A (en) Pharmaceutical composition comprising nabumetone
AU6460300A (en) Pharmaceutical compositions
AU6460100A (en) Pharmaceutical compositions
AU4543500A (en) Pharmaceutical compositions and uses
GB9904911D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase